Brazil is embarking on a significant transformation in its public health approach to diabetes management. The Ministry of Health has officially begun transitioning patients within the Sistema Único de Saúde (SUS)—the country’s universal healthcare system—from the traditional human NPH insulin to a more modern alternative: insulin glargine.
This shift represents a critical evolution in the quality of care for millions of Brazilians. By introducing a long-acting insulin analog, the government aims to provide more stable glycemic control, reduce the frequency of injections, and significantly lower the risk of dangerous hypoglycemic episodes. For patients who have long relied on the more volatile NPH insulin, the new insulin available in the SUS promises a higher degree of predictability and a simplified daily routine.
The transition is not merely a clinical upgrade but a strategic move to secure the national supply of essential medication. Following the establishment of an Insulin Working Group in November 2025, the Ministry of Health identified the need to modernize insulin therapy in response to global production restrictions on NPH and regular insulin according to official government reports. This initiative aligns with a broader federal policy to revitalize the Brazilian industrial complex, ensuring that the country can produce its own insulin after a two-decade hiatus.
Understanding the Clinical Advantage: Glargine vs. NPH
To understand why this transition is considered a historic advance, one must look at the pharmacological differences between the two medications. Insulin NPH (Neutral Protamine Hagedorn) is a human insulin that typically acts for about eight hours. Because of its shorter duration and the presence of “action peaks,” patients often require multiple injections throughout the day to maintain stable blood sugar levels.
In contrast, insulin glargine is an analog designed for slow, continuous release. It provides a basal coverage that lasts between 18 and 24 hours, allowing most patients to move to a single daily application as detailed by medical analysis. This stability is the cornerstone of the “advance” cited by health officials; by eliminating the peaks associated with NPH, glargine maintains more consistent glucose levels throughout the day and night.
From a safety perspective, the most significant gain is the reduction of hypoglycemia. According to Conitec, the body responsible for evaluating technology incorporation in the SUS, long-acting analogs are associated with a lower risk of hypoglycemic events, including nocturnal hypoglycemia per official reports. For vulnerable populations, such as children or the elderly, a sudden drop in blood sugar can lead to fainting or emergency hospitalizations, making the predictability of glargine a life-saving improvement.
Comparison of Insulin Types in the SUS Transition
| Feature | Insulin NPH (Traditional) | Insulin Glargine (New) |
|---|---|---|
| Action Type | Intermediate-acting human insulin | Long-acting insulin analog |
| Duration | Approximately 8 hours | 18 to 24 hours |
| Application Frequency | Often requires multiple daily doses | Typically a single daily dose |
| Hypoglycemia Risk | Higher due to action peaks | Lower due to stable release |
| Primary Benefit | Established, widely available | Better stability and adherence |
The Pilot Project: Priority Groups and Locations
The rollout of insulin glargine is being implemented gradually through a pilot project that began in February 2026. Rather than an immediate nationwide swap, the Ministry of Health is prioritizing the most vulnerable patient groups to ensure a safe and monitored transition.
The first phase of the project specifically targets:
- Children and adolescents up to 17 years of age living with Type 1 diabetes.
- Elderly patients aged 80 years or older living with either Type 1 or Type 2 diabetes.
This initial phase is being deployed in four specific locations: the state of Amapá, Paraná, Paraíba, and the Distrito Federal per official government data. The Ministry estimates that more than 50,000 people will be covered in this first stage of the rollout.
It is important for patients to note that the introduction of glargine does not signify that NPH insulin is being eliminated entirely or immediately. NPH remains a vital option within the SUS, and the transition is designed to expand the therapeutic toolkit available to doctors, allowing them to prescribe the most appropriate medication based on the patient’s specific clinical needs and risk profile.
Industrial Sovereignty and Public Health Security
Beyond the immediate clinical benefits for the patient, the transition to glargine is tied to Brazil’s national security regarding pharmaceutical supplies. The Ministry of Health has highlighted that the global market for NPH and regular insulin has faced significant production restrictions, which puts public health systems at risk of shortages.
Health Minister Alexandre Padilha has emphasized that the expansion of these treatments is a direct result of strengthening the Brazilian industrial complex. By utilizing the purchasing power of the SUS to stimulate domestic production, the federal government aims to guarantee that the population has permanent, free access to essential medications according to official statements. The return of insulin production to Brazilian soil after twenty years is viewed as a safeguard against international supply chain volatility.
Key Takeaways for Patients and Caregivers
- Improved Stability: Glargine provides a steady level of insulin for up to 24 hours, reducing the “peaks and valleys” of blood glucose.
- Easier Routine: The shift toward a single daily injection typically improves patient adherence to treatment.
- Enhanced Safety: There is a marked reduction in the risk of nocturnal hypoglycemia, which is especially critical for children and the elderly.
- Gradual Rollout: The transition is currently a pilot program in Amapá, Paraná, Paraíba, and Distrito Federal, focusing on those under 17 and over 80.
- Continued Access: NPH insulin remains available and is still a valid treatment option for many.
What So for the Future of Diabetes Care
The transition to insulin glargine marks a shift toward “precision” in public health—moving away from a one-size-fits-all approach to a system that offers more sophisticated, safer options for those who need them most. For a physician, the ability to prescribe a long-acting analog means fewer emergency room visits for hypoglycemia and better long-term A1c levels for the patient.
As the pilot project progresses, the Ministry of Health will monitor the outcomes in the four initial states to refine the protocol before expanding the offer to other regions of Brazil. This data-driven approach ensures that the transition is not only fast but clinically sound.
The next confirmed checkpoint for this initiative involves the ongoing monitoring of the 50,000+ patients in the pilot phase to determine the efficacy and safety metrics that will guide the nationwide expansion. Patients seeking more information on eligibility should consult their primary care physician within the SUS network or visit the official Ministry of Health portals for updated guidelines.
Do you or a family member leverage insulin provided by a public health system? We invite you to share your experiences with treatment adherence and the impact of long-acting insulins in the comments below.